Lymphoma drug combo trial halted early – what we know
NCT ID NCT03769181
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-stage trial tested two drugs, isatuximab and cemiplimab, together in 58 people with relapsed or refractory lymphoma. The goal was to see if the combination was safe and could shrink tumors. The study was terminated early, so while some safety and response data were collected, the full potential of this approach remains unclear.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
isatuximab and cemiplimab
What this could lead to
If successful, this combination could offer a new treatment option for people with certain types of lymphoma that have not responded to other therapies.
What could go wrong
The trial was terminated early, so results are limited. It is still early-stage research, and the combination may not prove effective or safe for broader use.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Investigational Site Number :1580002
Taichung, 40447, Taiwan
-
Investigational Site Number :2500001
Villejuif, 94800, France
-
Investigational Site Number :2500002
Nantes, 44093, France
-
Investigational Site Number :2500004
Montpellier, 34295, France
-
Investigational Site Number :2500005
Dijon, 21000, France
-
Investigational Site Number :2500007
Pessac, 33600, France
-
Investigational Site Number :3800002
Bologna, 40138, Italy
-
Investigational Site Number :3800003
Rozzano, Milano, 20089, Italy
-
Investigational Site Number :3800006
Brescia, 25123, Italy
-
Investigational Site Number :4100001
Gangnam-gu, Seoul-teukbyeolsi, 06351, South Korea
-
Investigational Site Number :4100002
Seoul, Seoul-teukbyeolsi, 03080, South Korea
-
Investigational Site Number :5280001
Maastricht, 6229 HX, Netherlands
-
Investigational Site Number :5280002
Amsterdam, 1081 HV, Netherlands
-
Investigational Site Number :6200002
Coimbra, 3000-075, Portugal
-
Investigational Site Number :6200003
Porto, 4200, Portugal
-
Investigational Site Number :6200004
Lisbon, 1649-035, Portugal
-
Investigational Site Number :7240002
L'Hospitalet de Llobregat, Barcelona [Barcelona], 08908, Spain
-
Investigational Site Number :7240003
Barcelona, Barcelona [Barcelona], 08035, Spain
-
Investigational Site Number :7240004
Madrid / Madrid, Madrid, Comunidad de, 28040, Spain
-
Investigational Site Number :7240005
Barcelona, Barcelona [Barcelona], 08036, Spain